Is GLP-1 the Same as Mounjaro, or Is There More to It?

What 'GLP-1 medicine' actually means, and where Mounjaro sits

When people say 'GLP-1 medication', they usually mean a class of drugs that mimic a hormone your gut releases after eating. That hormone (glucagon-like peptide-1) signals to your brain that you have eaten, slows how quickly your stomach empties, and helps regulate blood sugar. Medicines that replicate this effect are called GLP-1 receptor agonists.

Mounjaro belongs to this broader conversation, but it is not quite a GLP-1-only drug. Tirzepatide, the active ingredient in Mounjaro, was designed to activate a second gut-hormone receptor as well: GIP, or glucose-dependent insulinotropic polypeptide. Both GLP-1 and GIP play roles in appetite and energy balance, and working on both pathways simultaneously is what sets Mounjaro apart from single-receptor medicines like semaglutide.

The NHS medicines page for tirzepatide describes it as a dual GIP and GLP-1 receptor agonist, useful reading if you want the clinical framing in plain language. In everyday conversation, Mounjaro often gets lumped in with 'GLP-1 jabs', and that is broadly understandable; the GLP-1 mechanism is part of how it works. If you want to go deeper on exactly how GLP-1 relates to Mounjaro and where the label falls short, that question has its own dedicated page. You can also read more about tirzepatide's mechanism on the treatment overview.

That precision matters when you are comparing medicines, which is where most people are when they first ask this question.

The decision most people are actually trying to make

Nobody types 'is GLP-1 the same as Mounjaro' for purely academic reasons. The real question is almost always: are these medicines interchangeable, and does it matter which one I take?

They are not interchangeable in any straightforward sense. Mounjaro and semaglutide-based medicines (such as Wegovy) both reduce appetite and body weight, and both carry a once-weekly injection schedule, but their receptor profiles are different and trial data show different average outcomes. In the SURMOUNT-1 trial, tirzepatide at 15 mg produced average body-weight reductions of around 20–21% over 72 weeks, figures that led NICE to recommend it for eligible adults under TA1026, published in December 2024. Whether you are comparing the two medicines or trying to understand what category Mounjaro falls into, the receptor difference is the key fact to hold onto.

There is also a practical licensing point. In the UK, Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or from 27 with at least one weight-related condition. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of that changes based on what you call the drug class, but it does shape whether a prescriber can offer it to you. The full eligibility picture is set out on our treatment page.

If you are trying to decide between tirzepatide and semaglutide, rather than understand the mechanism, the relationship between GLP-1 and tirzepatide is worth reading as a companion piece.

What the dual-agonist difference means in practice

Adding GIP receptor activation is not just a marketing point. GIP receptors are expressed in fat tissue and in parts of the brain involved in appetite regulation. Some researchers believe the combination produces additive effects on satiety and energy expenditure that neither pathway achieves alone. That hypothesis informed the SURMOUNT clinical programme and is reflected in the trial results.

For anyone starting treatment, the practical implication is that the dose titration schedule exists to let your body adjust to both mechanisms at once. Treatment begins at 2.5 mg (a tolerability step) and moves upward at intervals the prescriber sets, including all the way up to the 16 mg maintenance dose for those who reach that stage. The side-effect profile is broadly similar to other medicines in the GLP-1 class: nausea, constipation, and other gastrointestinal symptoms are most common in the early weeks. Knowing that Mounjaro works on two pathways does not change how you manage those effects day-to-day, but it does explain why you cannot simply swap it for a single-agonist medicine at an equivalent dose.

One thing our prescribers hear regularly: people who have read about the dual mechanism want to know if it means higher risk. The trial evidence does not support that conclusion. The side-effect categories are the same as the wider class; the frequency profiles are comparable. For a more detailed look at how Mounjaro compares to other medicines by mechanism and outcome, this question has its own dedicated page. And if cost is part of your thinking, Mounjaro pricing in the UK explains what private treatment currently involves.

The one area where the dual-agonist label has a concrete effect on what you do is contraception. Women taking oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, because GLP-1 medicines can slow gastric emptying enough to affect pill absorption. That guidance comes from the NHS and is worth raising at your consultation rather than after you have started.

Getting clarity before you decide

The question of whether GLP-1 is the same as Mounjaro tends to arise at the research stage, before someone has spoken to a prescriber. If you are at that stage, it is a good sign, understanding the mechanism means you will ask better questions. The next step is a clinical assessment, where a prescriber reviews your health history, current medicines, and weight-related conditions to decide whether Mounjaro is appropriate for you and, if so, where to start.

At nume, every consultation is read and decided by a GPhC-registered Independent Prescriber. No automated triage, no algorithm, a real clinician reviews your answers the same day. Orders placed before midday on a working day are dispatched the same day once clinically approved, arriving via tracked DPD delivery the next working day. If you tend to plan around paydays or want to time a Monday start, that same-day dispatch window is worth knowing about.

For a broader look at what treatment involves before starting a consultation, the weight-loss treatment overview covers the full picture. When you are ready, our team is available to review your eligibility.